AI summary by TwinMind
The trials, tribulations and timeline of a COVID-19 vaccine | Jerome Kim
TED
23m 32s
Vaccine Development Overview
- Normal vaccine development: 5-10 years, ~$1 billion cost, 93% failure rate
- COVID-19 accelerated timeline: 12-18 months under pandemic pressure
- Pandemic context: 8 million infections, 400,000 deaths at time of discussion
- Four key challenges:
- Prove vaccine works (likely achievable)
- Develop in 12-18 months (tougher but possibly achievable)
- Manufacture sufficient quantity with quality at affordable cost (tougher challenge)
- Ensure equitable access for all (toughest challenge)
COVID-19 vs HIV Vaccine Development Comparison
- Key difference: Natural immunity patterns
- COVID-19: Evidence suggests people develop protection against reinfection (at least temporarily)
- HIV: No natural immunity - reinfection possible, indicating insufficient immune response
- Animal model validation:
- Three reports of human COVID-19 vaccines protecting monkeys against challenge
- Non-human primate protection provides important proof of concept
- Measles/Hepatitis A analogy: Body eliminates virus and prevents reinfection
Vaccine Development Approaches
- Nucleic acid vaccines (fastest development):
- RNA vaccines: Moderna developed concept within days of sequence publication, vaccine made within week, human testing 8 weeks after sequence announcement
- DNA vaccines: Inovio began human testing in April
- Vectored vaccines:
- Use genetic information inserted into another virus (commonly adenovirus)
- Chinese CanSino: adenovirus type 5 vector
- Oxford/AstraZeneca: chimpanzee adenovirus vector
- Johnson & Johnson (Janssen): ad type 26 vector
- Whole inactivated virus vaccines:
- Grow virus in cells, harvest, purify, kill with heat/formalin
- Relatively easy to make, cheap
- Example: inactivated polio vaccine
Vaccine Efficacy Expectations
- Target: >60-70% effectiveness
- Limited human data available at time of discussion:
- Moderna: reported on 8 out of 45 people in phase 1 trial
- Some CanSino (ad5-based) data emerging
- Small animal data from Inovio (DNA) and Moderna (RNA)
- FDA, European regulators, WHO require sufficient precision around estimates
- Need clear demonstration of safety and efficacy
Disease Impact Distribution
- 80% of people: asymptomatic or mild symptoms
- 14-15% of people: significant symptoms
- 5% of people: very sick
- 2-3% of people: die
- Similar pattern to other diseases (measles example)
- Single vaccine typically protects across all severity levels
- Vaccine resistance develops more slowly than antibiotic resistance
- Exception: influenza vaccine (unknown if COVID-19 will follow similar pattern)
Safety and Side Effects
- Most side effects occur within first 1-3 months post-vaccination
- Longer-term effects require extended observation periods and larger populations
- Government regulatory agencies (FDA, EMA) established surveillance systems for adverse events
- Can detect effects under 1% occurrence rate
- Clinical trial observation typically 1-2 years
- Vaccines pushed toward efficacy while maintaining safety focus
Manufacturing and Distribution Challenges
- Normal process: plan manufacturing in final years of 5-10 year cycle
- COVID-19 compressed timeline requires simultaneous development and manufacturing
- Operation Warp Speed: US government manufacturing "at risk"
- Government underwrites financial risk for manufacturers
- Allows production before knowing if vaccine works
- Enables immediate availability if proven safe/effective
- Global partnership strategy:
- Individual companies partner with manufacturers in South America, India, Korea, Japan
- Goal: produce required billions of doses
- Dose requirements:
- One shot: ~7 billion doses
- Two shots: ~14 billion doses
- With boosters: additional billions
Correlative Protection Development
- Goal: identify lab test indicating protection level
- Enables smaller, faster trials instead of 30,000-person phase 3 trials
- Reduces development time and cost for vaccine modifications
- Critical for future vaccine improvements and booster development
Global Access and Allocation Strategy
- Country-first approach: Nations funding development prioritize own populations
- Coalition for Epidemic Preparedness Innovations (CEPI):
- 15+ countries, Gates Foundation, Wellcome Trust, European Union
- $2 billion portfolio for rapid vaccine development
- Funded many companies entering Phase 2
- Requires companies to sign global access agreements
- Ensures adequate supply at reasonable cost
- International coordination needs:
- WHO, UN, other organizations should plan allocation now
- Decisions needed before first vaccine available
- Transparent, principled allocation framework required
- Avoid "us first" pressure when vaccine becomes available
Regulatory Standards and Quality Control
- WHO developed target product profile for vaccine review
- International regulatory coordination:
- US FDA, European EMA, WHO collaboration
- Unified minimum effectiveness standards
- Rapid approval processes for qualifying vaccines
- Goal: reduce variation in acceptable vaccine effectiveness levels globally
